Xtant Medical

Investors

Corporate Profile

Xtant Medical Holdings, Inc. (NYSE MKT: XTNT) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries.


Stock Quote
XTNT (Common Stock)
Price$0.63
Change (%) - 0.12 (16.00%)
Volume1,004,156
Data as of 11/21/17 4:10 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart


Recent News
DateTitle 
11/21/17Xtant Medical Reports Third Quarter 2017 Financial Results
Company restructuring efforts continue to gain traction towards profitability Third Quarter 2017 Highlights Reported third quarter 2017 revenue of $19.8 million compared to $23.1 million reported during the third quarter of 2016 Operating Expenses decreased 17% to $14.9 million, compared to $17.9 million reported during the third quarter of 2016 Third quarter 2017 EBITDA of $1.4 million compared to $0.7 million reported during the third quarter of 2016   Company management to host... 
11/09/17Xtant Medical Postpones Release of Third Quarter 2017 Financial Results
BELGRADE, Mont., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, announced that it has postponed the release of its third quarter 2017 financial results, originally scheduled for Wednesday, November 8, 2017, and conference call, originally scheduled for Thursday, November 9, 2017. The Company now plans to release its third quarter 2017 financial results in conjunction with... 
11/01/17Xtant Medical Enters into a Distribution Agreement with curasan, Inc. Bringing Matriform™ to Market
BELGRADE, Mont., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced it has entered into a distribution agreement with curasan, Inc. adding a premium line of synthetic scaffolds to its biologics portfolio.  Matriform, Xtant’s brand of the curasan synthetic product portfolio for orthopedic applications, consists of a composition of pure phase Beta-Tricalcium Pho... 
10/27/17Xtant Medical to Announce Third Quarter 2017 Results on Wednesday, November 8th 
BELGRADE, Mont., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the third quarter ended September 30, 2017, after the close of the financial markets on Wednesday, November 8th, 2017. An accompanying conference call will be conducted by Carl O'Connell, Chief Executive Officer and President, and Laura Kendall, I... 
More


Upcoming Events
There are currently no events scheduled.
More

Receive Email Alerts
Sign up to receive email alerts whenever Xtant Medical Holdings Inc posts new information to the site. Just enter your email address and click Submit.